X, liquid E, and special K - The abuse of drugs at clubs and raves

American Journal of Pharmaceutical Education

Volumn 66, Issue 2, 2002, Pages 195-199

  Romanelli, Frank ^a,b   Smith, Kelly M ^a  

^a University of Kentucky   (United States)

^b Department of Pharmacy ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33745328105     PISSN: 00029459     EISSN: 15536467     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Seper, J., "Threat of 'Ecstasy' reaching cocaine, heroin proportions," Washington Times, (August 16, 2000).
2. Johnston, L.D., O'Malley, P.M. and Bachman, J.G., "Monitoring the Future: National Results on Adolescent Drug Use - Overview of Key Findings, 2000," Ann, Arbor, MI, University of Michigan Institute for Social Research; Rockville, MD, National Institute on Drug Abuse (2001).
3. Epidemiologic Trends in Drug Abuse: Advance Report, December 2000; Community Epidemiology Work Group, National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH), Bethesda MD, (June 2000).
4. Nichols, D.E. and Oberlender, R., "Structure-activity relationships of MDMA-like substances," NIDA Res Monographs, 94, 1-29(1989).
5. ( 5) U.S. Senate Caucus on International Narcotics Control: Statement of the Director. July 25, 2000 .
6. Community Drug Alert Bulletin. NIDA. Http://165.112.78.61/clubalert/ clubdrugalert.html. (accessed 2001 May).
7. FDA approves clinical test of ecstasy. Http://www.cnn.com/2001/health/11/ 07/ecstasy.test.ap/index.html
8. Tetter, C.J. and Guthrie, S.K., "A comprehensive review of MDMA and GHB: Two common club drugs" Pharmacotherapy, 21, 1486-1513(2001).
9. Rattray, M., "Ecstasy: Towards an understanding of the biochemical basis of the actions of MDMA," Essays Biochem., 26, 77-87(1991).
10. Schwartz, R.H. and Miller, N.S., "Ecstasy and the rave: A review," Pediatrics, 100, 705-708(1997).
11. Morland, J., "Toxicity of drug abuse - Amphetamine designer drugs (ecstasy): Mental effects and consequences of single dose use," Toxicol. Lett., 112-113, 147-152(2000).
12. Tools of the raver. Http://www.streetdrugs.org/rave.htm. (accessed 2001 May).
13. Grame, K.A., "Pharmacologic advances in emergency medicine," Emergency Medicine Clinics of North America, 18, 2190(2000).
14. Holmes, S.B., Banerjee, A.K. and Alexander, W.D., "Hyponatremia and seizures after ecstasy use," Post Grad. Med. J., 75, 32-34(1999).
15. Green, A.R, Cross, A.J. and Goodwin, G.M., "Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy")," Psychopharmcol, 119, 247-260(1995).
16. Mueller, P.D. and Korey, W.S., "Death by "ecstasy": The serotonin syndrome?," Ann. Emerg. Med., 32, 377-380(1998).
17. Ricaurte, G.A., McCann, U.D., Szabo, Z., et al., "Toxicodynamics and long-term toxicity of the recreational drug, 3-4-methylemedioxymethamphetamine (MDMA, "ecstasy")," Toxicol. Lett. 112-113, 143-146(2000).
18. Christophersen, A.S., "Amphetamine designer drugs - An overview and epidemiology," ibid., 112-113, 127-131(2000).
19. Vayer, P., Mandel, P. and Maitre, M., "Gamma-hydroxybutyrate, a possible neurotransmitter," Life Sci., 41, 1547-1557(1987).
20. Vickers, M.D., "Gamma-hydroxybutyric acid," Int. Anesth. Clin., 7, 75-79(1969).
21. Fry, J.M., "Treatment modalities for narcolepsy," Neurology, 50, S27-S30(1998).
22. Smith, K.M., "Drugs used in acquaintance rape," J. Am. Pharm. Assoc., 39, 519-525(1999).
23. Goldfrank, L.R., Lewin, N.A. and Weisman, R.S. "Dieting agents and regimens," in Goldfrank's Toxicologic Emergencies, (edit., Goldfrank, L.R.), Appleton & Lange, East Norwalk CT (1994) pp. 552.
24. Centers for Disease Control and Prevention, "Multistate outbreak of poisonings associated with illicit use of gamma-hydroxybutyrate.," JAMA, 265, 447-448(1991).
25. Centers for Disease Control and Prevention., Adverse events associated with ingestion of gamma-butyrolactone - Minnesota, New Mexico, and Texas, 1998-99., MMWR, 48, 137-140(1999).
26. Kohrs, P.P. and Porter, W.H., "Gamma-hydroxybutyrate intoxication and overdose," Ann. Emerg. Med., 33, 475-476(1999).
27. Mamlak, M., "Gamma-hydroxybutyrate: An endogenous regulator of energy metabolism," Neurosci. Biobehav. Rev., 13, 187-198(1989).
28. Eckstein, M., Henderson S.O., Delacruz P., et al, "Gamma- hydroxybutyrate (GHB): Report of a mass intoxication and review of the literature," Prehospital. Emergency Care, 3, 357-361(1999).
29. Tunnicliff, G., "Significance of gamma-hydroxybutyric acid in the brain," Gen. Pharmcol., 23, 1027-1034(1992).
30. Takahara, J., Yunoki, S., Yakushiji, W., et al., "Stimulatory effects of gamma-hydroxybutyric acid on growth hormone and prolactin release in humans," J. Clin. Endocrinol. Metab., 44, 1014-1016(1997).
31. Li, J., Arnaud-Sotkes, S. and Woeckener, A., "A tale of novel intoxication: A review of the effects of gamma-hydroxybutyric acid with recommendations for management," Ann. Emerg. Med., 31, 1729-1736(1998).
32. Palatani, P., Tedeschi, L., Frison, G., et al., "Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteers," Eur. J. Clin. Pharmacol., 45, 353-356(1993).
33. Garrison, G. and Muller, P., "Clinical features and outcomes after unintentional gamma-hydroxybutyrate (GHB) overdose," J. Clin. Toxicol., 36, 503-504(1998).
34. Chin, R.L., Sporer, K., Cullison, B., et al., "Clinical course of gamma-hydroxybutyrate overdose," Ann. Emerg. Med., 31, 723-728(1998).
35. Dyer, J.E., "Gamma-hydroxubutyrate: A health food product producing coma and seizure-like activity," Ann. Emerg. Med., 9, 321-324(1991).
36. Shannon, M. and Quang, L.S., "Gamma-hydroxybutyrolactone, 1-4,-butanediol: A case report and review of the literature," Pediatric Emergency Care, 16, 435-440(2000).
37. Badcock, N.R. and Zotti, R., "Rapid screening test for gamma-hydroxybutyric acid in urine (letter)," Ther. Drug Monit., 21, 376(1999).
38. Dyer, J.E., "Gamma-hydroxybutyrate (GHB)," in Poisoning and Overdose, Appleton & Lange, Stamford CT (1999) pp. 179-181.
39. Kohrs, R. and Durieux, M.E., "Ketamine teaching an old dog new tricks," Anesth. Analg., 87, 1186-1193(1998).
40. Romack, B.H., Toll, L.L. and Gelman, C.R., (edits.), POISONDEX System. Englewood, Colo: MICROMEDEX, Inc; (Vol. 108, expired 6/30/01).
41. Jansen, K.L.R., "Nonmedical uses of ketamine," Br. Med. J., 19, 53-63(1997).
42. Fox, M., "Date rape drugs widely abused Congress told [news wire release]. Reuters: March 11, 1999.
43. Krystal, J.H., Karper, L.P. Seibyl, J.P., et al., "Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychometeric, perceptual, cognitive, and neuroendocrine responses," Arch. Gen. Psychiatry, 51, 199-214(1994).
44. Moore, K.A., Kilbane, E.M., Jones ER, et al, "Tissue distribution of ketamine in a mixed drug fatality,"" J. Forensic Sci., 2, 1183-1185(1997).
45. Hansen, G. and Jansen, S.B., Chandresh L, et al., "The psychotropic effect of ketmaine," J. Psychoactive Drugs, 20, 419-425(1988).
46. Reich, D.L. and Silvay, G., "Ketamine: An update on the first twenty-five years of clinical experience," Can. J. Anaesth., 36, 186-197(1989).
47. Zancy, J.P. and Galinkin, J.L., "Psychotropic drugs used in anaesthesia practice and abuse liability and epidemiology of abuse," Anesthesiology, 90, 269-288(1999).
48. Vieira, L. and Weiner, A., "Ketamine abusers presenting to the emergency department: A case series," J. Tox. Clin. Tox., 36, 505(1998).